MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Open Access Journal of Pharmaceutical Research
ISSN: 2574-7797

RNA Therapeutics in 2026: The Delivery Challenge Beyond mRNA Vaccines

Bennett OJ*

Department of Pharmaceutics and Drug Delivery, Westford Institute of Pharmaceutical Research, United Kingdom

***Corresponding author:** Oliver J Bennett, Department of Pharmaceutics and Drug Delivery, Westford Institute of Pharmaceutical Research, United Kingdom

Mini Review
Volume 10 Issue 2
Received Date: May 01, 2026
Published Date: May 20, 2026

Abstract

RNA therapeutics have evolved from a promising molecular concept into a clinically relevant pharmaceutical platform. Antisense oligonucleotides, small interfering RNA, messenger RNA and emerging RNA modalities can regulate protein expression without requiring conventional small-molecule binding to a protein pocket. The major pharmaceutical challenge is delivery: RNA molecules are large, negatively charged and vulnerable to degradation, and their therapeutic activity depends on reaching the correct cells and intracellular compartments. Lipid nanoparticles (LNPs), conjugates and other delivery systems have therefore become central to RNA drug development. This mini review summarises the major RNA therapeutic classes, delivery principles, formulation challenges and emerging directions in 2026, with emphasis on tissue targeting, repeat dosing, tolerability, manufacturing and translational barriers.

Keywords: RNA Therapeutics; mRNA; siRNA; Antisense Oligonucleotides; Lipid Nanoparticles; Drug Delivery; Nucleic Acid Medicines

Introduction

RNA therapeutics have changed the conceptual boundaries of pharmaceutical science. Traditional drugs generally act by binding proteins or other molecular targets, whereas RNA medicines can modify the information flow that produces proteins. This creates opportunities for diseases in which conventional targets are difficult to drug. RNA technologies include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), mRNA, aptamers and other engineered RNA molecules. A recent 2026 review describes the field as progressing from early antisense and RNA-interference approaches toward increasingly diverse therapeutic applications [1].

The clinical success of mRNA vaccines demonstrated that nucleic acids can be manufactured and administered at scale. However, vaccines are only one application. The broader goal is to develop RNA medicines that can be delivered repeatedly, selectively and safely to tissues beyond the liver.

Major RNA Therapeutic Classes

ASOs are short synthetic nucleic acids designed to bind complementary RNA sequences. Depending on their chemistry and design, they can alter splicing, reduce target

CC BY

RNA or modulate translation. siRNA operates through the RNA interference pathway and can induce sequence-specific degradation of target messenger RNA. Both approaches have already established important proof of clinical feasibility.

mRNA follows a different strategy. Instead of suppressing a gene, therapeutic mRNA provides transient instructions for cells to produce a desired protein. This makes mRNA attractive for vaccines, protein replacement and potentially cancer immunotherapy. The transient nature of RNA expression can be an advantage when permanent genetic modification is undesirable.

The common pharmaceutical requirement across these modalities is controlled intracellular delivery. RNA activity depends not only on the amount administered but on whether an adequate fraction reaches the correct cell and escapes intracellular degradation pathways.

Why Lipid Nanoparticles Matter

LNPs became a defining delivery technology for mRNA medicines because they can protect RNA from degradation and facilitate cellular uptake. Their composition generally includes ionisable lipids, helper lipids, cholesterol and a lipid component that influences particle stability and pharmacokinetics. The field has increasingly moved toward engineering the particle as a biological delivery system rather than viewing it simply as an inert carrier.

Recent work emphasises system-level design, in which particle properties are considered together with biological barriers, biodistribution and target-cell biology [2]. This is particularly important because a formulation that performs well in one tissue may not perform well in another. Liver delivery has been relatively successful, while extrahepatic delivery remains a major frontier.

The 2026 Delivery Agenda: Targeting and Repeat Dosing

One of the most important goals is selective delivery to tissues such as lung, muscle, immune cells and the central nervous system. Researchers are exploring ionisable lipid chemistry, biodegradable materials, targeting ligands, polymers and alternative administration routes.

Repeat dosing creates an additional challenge. The immune system may recognise components of a delivery system, and repeated exposure can alter pharmacokinetics or tolerability. A 2026 report describes poly(D,L-serine)-based lipid alternatives being investigated to replace PEG-lipid functions in LNPs, motivated partly by concerns surrounding anti-PEG antibodies and repeat administration [3].

The pharmaceutical significance is substantial: a successful RNA medicine may require not just efficient first-dose delivery but predictable performance over months or years of treatment.

Manufacturing and Stability

RNA medicines are also formulation and manufacturing challenges. RNA can be sensitive to degradation, while nanoparticle size, encapsulation efficiency, lipid composition and impurities can influence biological performance. Manufacturing processes must therefore control both the RNA product and the delivery system.

Cold-chain requirements have historically complicated some nucleic-acid products. Improved RNA chemistry and formulation stability may broaden access, particularly in settings where sophisticated distribution infrastructure is limited. The long-term objective is a platform that can be manufactured reproducibly, stored reliably and administered without excessive logistical burden.

Safety and Pharmacology

RNA medicines require careful evaluation of innate immune activation, off-target effects, tissue distribution and duration of action. The desired effect is usually sequence-specific, but unintended interactions can occur. Delivery systems themselves can influence inflammatory responses, complement activation or tissue accumulation.

Pharmacokinetic assessment also differs from that of conventional small molecules. Researchers may need to distinguish intact RNA, metabolites, carrier components and pharmacodynamic protein changes. Thus, RNA pharmacology increasingly requires integrated measurement of exposure, intracellular delivery and biological effect.

Emerging Applications

Beyond infectious-disease vaccines, RNA platforms are being investigated for cancer, genetic disorders, metabolic disease and protein replacement. mRNA may enable transient production of therapeutic proteins, while siRNA and ASOs can silence disease-associated pathways. RNA delivery is also being explored for genome-editing components, where transient expression may provide an alternative to permanent exposure [4-5].

The next generation of products is likely to be defined by precision delivery rather than RNA sequence alone. In other

Copyright© Bennett OJ.

words, the central question is moving from “Can we design an effective RNA?” to “Can we deliver the right RNA to the right cell at the right dose for the right duration?”

Conclusion

RNA therapeutics represent one of the most important pharmaceutical platforms of the current decade. The scientific foundation is increasingly mature, but delivery remains the limiting factor for many applications. Advances in LNP chemistry, targeted delivery, biodegradable materials, manufacturing and analytical characterisation are gradually expanding the therapeutic landscape. In 2026, the field is best viewed not as a single technology but as an integrated discipline combining nucleic-acid chemistry, pharmaceutics, nanomedicine, molecular biology and clinical pharmacology. The next major breakthroughs are likely to come from delivery systems that are more tissue-selective, repeat-dose compatible, manufacturable and accessible.

References

1. Singh A, Tekade M, Nagaraja S, Bharti A, Tekade RK (2026) Advancements in RNA-based therapies from bench to bedside. npj Drug Discovery 3: 4.

2. Han EL, Mitchell MJ (2026) System-level design of lipid nanoparticles for targeted RNA delivery. Nature Reviews Bioengineering. Nature Chemical Engineering.

3. Zeng JY, Zhang Y, Zhao G, Seow BYL, Krishnan NB, et al. (2026) Polypeptide-engineered lipid nanoparticles for mRNA delivery. Nature Communications 17: 6986.

4. Hou X, Zaks T, Langer R, Dong Y (2021) Lipid nanoparticles for mRNA delivery. Nature Reviews Materials 6: 1078–1094.

5. Paunovska K, Loughrey D, Dahlman JE (2022) Drug delivery systems for RNA therapeutics. Nature Reviews Genetics 23: 265-280.

Copyright© Bennett OJ.